Injection Site Tolerability, Safety, Pharmacokinetics and Pharmacodynamics Study After a Single Dose Subcutaneous Treatment of Alirocumab SAR236553 (REGN727)

NCT01448239 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

24

Enrollment

INDUSTRY

Sponsor class

Conditions

Hypercholesterolemia

Interventions

DRUG: alirocumab SAR236553 (REGN727)
DRUG: alirocumab SAR236553 (REGN727)

Sponsor

Sanofi

Collaborators

[object Object]